Recent Pharmaceutical Dosage Form

Pulmatrix Expands Scientific Advisory Board, Adding World-Renowned Scientists ...

LEXINGTON, Mass.--( BUSINESS WIRE )-- Pulmatrix , a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it was expanding the company’s Scientific Advisory Board to help advance the company’s research and clinical studies. This Scientific Advisory Board will examine and support the scientific advancements that underlie the company’s novel inhaled cationic airway lining modulators (iCALM)™ platform, which has lead clinical candidates for COPD, asthma, and CF. Joining Pulmatrix’s Scientific Advisory Board are Richard Ulevitch, PhD, Tony Hickey, PhD, Peter Barnes, MD, Charles Wira, PhD, David Clapham, MD, PhD, Sanjay Sethi, MD, Mary Fitzgerald, PhD, and Richard Boucher, MD.

“We are committed to developing a new paradigm in the treatment and control of chronic respiratory diseases like COPD and CF, and we have made great strides thus far, with the advancing clinical trials of our iCALM product candidates,” said Robert Connelly , CEO of Pulmatrix. “We are delighted that such a strong group of world-renowned scientific leaders will be joining Pulmatrix’s Scientific Advisory Board to help us advance this novel approach. Our Scientific Advisory Board members are truly 'hands on' advisors who are very involved in the key strategies, decisions and often the execution of our iCALM research and formulation plans, clinical trial programs, and Pulmatrix's drug development programs.”

Professor Richard Boucher, MD, has extensive experience in the study of the pathophysiology and therapy of chronic airways diseases, including cystic fibrosis. He is currently a William Rand Kenan Professor of Medicine at the University of North Carolina, the Chief of Pulmonary Medicine, Director of the UNC Cystic Fibrosis/Pulmonary Research and Treatment Center, and Co-Director of the UNC Gene Therapy Center. He has published more than 400 papers on all aspects of pulmonary medicine and cystic fibrosis. In addition, Dr. Boucher was a founder of Inspire Pharmaceuticals, a biotechnology company focused on developing novel nucleotide-based therapies for the treatment of lung disease. Dr. Boucher is Co-Founder & Chairman of the Board of Parion, a privately held development-stage pharmaceutical company focused on the discovery and development of new treatments for pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. He holds more than 30 patents focused on novel therapies of lung diseases. He received his BA from Yale University and his MD from Columbia University.

Pharmaceutical excipients constantly breaking new trends in ...

Currently facing pharmaceutical preparations to improve quality and reduce cost pressures, Pharmaceutical Excipients And the preparation of the boundaries of the active ingredient in smaller profits began to close, medicinal Accessories R & D and production has become a new growth point in the pharmaceutical industry. In the recently held "The Second China Pharmaceutical Excipients standard use of the" Forum on China Pharmaceutical University, said James family health in recent years, research and application of medical accessories, some new trends have emerged, such as development of multi-purpose accessories, new dosage forms development needs to accelerate development of new pharmaceutical excipients. Recent years, varieties of blockbuster drugs, fewer and fewer profits are significantly reduced; and a large number of patent medicine patent expires, the impact on the market increases; the same time governments to lower drug prices and improve product quality dual requirements reduced the profit margins of pharmaceutical companies. Some large international pharmaceutical companies reluctant to accept the high input, low output of reality, seeking cheap, high quality medical accessories become more and more pressing demands. Traditionally, we think that pharmaceutical excipients should be inert (inert chemical and physical), now the industry is in the nature of pharmaceutical excipients to form a new consensus that is not necessarily an inert pharmaceutical excipients. Tu family health, said more and more evidence that there is biological activity accessories, some accessories, such as sodium cholate, HP-CD, propylene glycol, polyethylene glycol 400, etc., can promote the oral absorption of insoluble drugs; many accessories such as CremophorEL , RH40, Tween20, 80, Span20, PluronicP85, TPGS, Brij30, Myrj52andGelucire44/14 can significantly inhibit the efflux of P-GP, and improve drug absorption. In addition, many pharmaceutical excipients on the pharmacokinetics of injections have great influence, such as cyclodextrin can be lipid, such as lipoprotein, Cholesterol Interaction with the drug combination and the release of water on the pharmacokinetics of drugs influenced the blood.

Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems

Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms

New to the Third Edition: the interaction of drugs with functional polymers the influence of processing parameters on coating quality the stabilization of ...

Pharmaceutical dosage forms, parenteral medications

Pharmaceutical dosage forms, disperse systems

Remington, the science and practice of pharmacy

Coating of Pharmaceutical Dosage Forms ... in the early years of this development, an entirely new form of technology evolved, namely that of film coating. ...